Observational studyRenal failure2026
Outcomes and predictors of kidney failure in elderly patients with biopsy-proven IgA nephropathy.
Observational study in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical presentation and prognosis of immunoglobulin A nephropathy (IgAN) in older adults are poorly defined. We evaluated kidney and patient outcomes and predictors of progression in patients aged ≥60 years with biopsy-proven IgAN. We conducted a retrospective observational study in elderly patients diagnosed with primary IgAN between 2010 and 2024 at a tertiary center. Baseline clinical, laboratory, and histopathologic data were collected, and kidney biopsies were scored using the Oxford MEST-C (Mesangial hypercellularity, Endocapillary hypercellularity, Segmental glomerulosclerosis, Tubular atrophy/interstitial fibrosis, Crescents) classification. The primary outcome was a composite of end-stage kidney disease (ESKD) or death. Predictors of progression were assessed using Kaplan-Meier's analysis and Cox proportional hazards models. A total of 102 patients were included (median age 65 years; 73% male). Comorbidity burden was high (median Charlson Comorbidity Index 4), hypertension was prevalent (88%), and baseline kidney function was reduced (median estimated glomerular filtration rate (eGFR) 29.5 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.